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Abstract Myosin binding protein C (MYBPC) is a cru-
cial component of the sarcomere and an important regu-
lator of muscle function. While mutations in different
myosin binding protein C (MYBPC) genes are well known
causes of various human diseases, such as hypertrophic
(HCM) and dilated (DCM) forms of cardiomyopathy
as well as skeletal muscular disorders, the underlying
molecular mechanisms remain not well understood. A
variety of MYBPC3 (cardiac isoform) mutations have been
studied in great detail and several corresponding geneti-
cally altered mouse models have been generated. Most
MYBPC3 mutations may cause haploinsufﬁciency and with
it they may cause a primary increase in calcium sensitivity
which is potentially able to explain major features observed
in HCM patients such as the hypercontractile phenotype
and the well known secondary effects such as myoﬁbrillar
disarray, ﬁbrosis, myocardial hypertrophy and remodelling
including arrhythmogenesis. However the presence of
poison peptides in some cases cannot be fully excluded and
most probably other mechanisms are also at play. Here we
shall discuss MYBPC interacting proteins and possible
pathways linked to cardiomyopathy and heart failure.
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Abbreviations
DCM Dilated cardiomyopathy
HCM Hypertrophic cardiomyopathy
LMM Light meromyosin
MYBPC Myosin binding protein C (in italics: gene)
MYBPC1 Slow twitch isoform (in italics: gene)
MYBPC2 Fast twitch isoform (in italics: gene)
MYBPC3 Cardiac isoform (in italics: gene)
cMyBP-C Cardiac myosin binding protein C
PKA Protein kinase A
RLC Regulatory light chain
TnC, I, T Troponin C, I, T
For in that profession there is no such thing as coincidence.
(John le Carre ´)
Introduction—domain structure and binding
partners
Myosin binding protein C (also known as C-protein:
MyBP-C; cardiac isoform abbreviated: cMyBP-C) was
discovered in 1973 (Offer et al. 1973) and is located on 7–9
stripes of 43 nm spacing in each half of the A-band (cross
bridge bearing zone, C-region) of the sarcomere in skeletal
and cardiac muscles (Fig. 1). To date three different MY-
BPC proteins are known, each encoded by different genes
(MYBPC 1–3), where slow (MYBPC1, 1141 aa) and fast
(MYBPC2 1141 aa) twitch muscle isoforms are restricted
to skeletal muscle tissues and whereas MYBPC3 (1273 aa)
is expressed exclusively in cardiac myocytes (Furst et al.
1992; Gautel et al. 1995; Weber et al. 1993). All MYBPC
molecules share common architectural features: they are
composed of seven immunoglobulin domains (Ig) and three
ﬁbronectin type III domains (FnIII) called C1–10 where a
105 amino acid myosin binding protein motif is localized
between C1 and C2. In addition, a proline and alanine rich
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Domains C9–C10 interact with titin and C10 interacts with
light meromyosin (LMM) (Freiburg and Gautel 1996). The
actin and S2 (head region) myosin heavy chain binding
regions are located at the aminoterminus (Fig. 2). Skeletal
muscle MYBPC also interacts with nebulin, but this
interaction is not well studied (Jin and Wang 1991) (for a
review (Kontrogianni-Konstantopoulos et al. 2009)). Also
the MYBPC1-variant 1 interacts with the giant protein
obscurin (Ackermann et al. 2009). Another novel interac-
tion between the cardiac speciﬁc C0 domain and the reg-
ulatory light chain (RLC) has been analyzed by Ratti et al.
(2011).
In addition, domains in the mid-region (C5–C8) have
been hypothesized to interact with one another, forming a
‘‘trimeric collar’’ that constrains the thick ﬁlament (Mool-
man-Smook et al. 2002). Also, a slightly different model of
MYBPC organisation within the sarcomere has been pro-
posed by Squire et al. (2003). These authors due to struc-
tural considerations and because domains C7–C10 are also
reported to interact with titin, which is unlikely to run other
than axially along the myosin ﬁlament, propose a model
whereby the carboxyterminal end of MYBPC is aligned
axially, which contrasts the collar alignment structure
(Fig. 3).
Fig. 1 Electron micrograph of rat cardiac muscle labelled with a
MYBPC antibody. It shows that MYBPC in cardiac muscle occurs
over 9 stripes. The scale bar is 500 nm (Luther et al. 2008) (with
Dr Pradeep Luther’s kind permission)
Fig. 2 Depicts the structure of
MYBPC3 as well as highlights
important structural domains
and indicates MYBPC3
interacting proteins.
Please note: the number of
phosphorylation sites localized
in the MYBPC motif is species
dependent. Ig immunoglobulin,
P/A proline/alanine,
Fn ﬁbronectin)
Fig. 3 Summarizes the major differences between the MYBPC
models proposed by (Moolman-Smook et al. 2002)( a) and (Squire
et al. 2003)( b). Please note in a MYBPC forms a ‘‘trimeric collar’’
that constrains the thick ﬁlament (Moolman-Smook et al. 2002). Top:
schematic diagram showing a single MYBPC protein interacting with
myosin (‘‘top view’’), bottom: side view. Whereas in b the carboxy-
terminal end of MYBPC is aligned axially (Squire et al. 2003). Top
view: a thick ﬁlament is represented along with six surrounding actin
ﬁlaments (in striated muscle), the broken circle represents the C0
domain in the MYBPC3 isoform. Bottom: side view, domains C7–
C10 running axially along the myosin ﬁlament backbone. A few
myosin heads are drawn as ‘‘transparent’’ ghosts to indicate their
position (grey circles: MYBPC3 with green indicating the P/A rich
domain; yellow/brown: myosin, dark grey: actin; ﬁgures are from:
(Squire et al. 2003) with kind permission from the authors and the
publisher (Journal of Molecular Biology))
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cardiac and skeletal muscle isoforms: MYBPC3 consists of
an additional immunoglobulin domain (C0) at its amino-
terminus, the domain C5 contains a proline rich 25 residue
insertion and several phosphorylation sites are species
dependent localized in the myosin binding motif (Gautel
et al. 1995; Mohamed et al. 1998).
Implication in human disease
MYBPC3 mutations were ﬁrst reported in 1995, which was
an important discovery (Bonne et al. 1995; Watkins et al.
1995a). Indeed HCM is a frequent disease, affecting 1:500
individuals (Maron et al. 2006) and depending on the
population analyzed, MYBPC3 mutations are found in up to
40–50% of the genotyped HCM patients (Richard et al.
2003). To date about 200 different MYBPC3 mutations
have been reported (Marston 2011; Schlossarek et al.
2011). In general, MYBPC3 mutations are associated with a
slightly lower penetrance, later onset of disease and with
milder forms of disease progression in comparison to other
HCM causing mutations located for example in the beta
myosin heavy chain (MYH7) gene (Niimura et al. 1998;
Watkins et al. 1995b). However this general statement may
not necessarily be true for all MYBPC3 mutations and
indeed some MYBPC3 mutations are associated with a poor
prognosis. For example—a recently discovered deletion in
intron 32 in MYBPC3 (nt 21348-21372, accession no.
U91629), leading to a pre-terminal stop codon, has been
found at a frequency of about 4% in India and South East
Asia, with signiﬁcant impact on human heart failure
(Dhandapany et al. 2009; Waldmuller et al. 2003). While
this mutation has been initially described in HCM patients,
it is important to note that this mutation is also associated
with other types of cardiomyopathy such as DCM. Other
MYBPC3 mutations primarily found in DCM patients have
also been reported, for example the Asn948Thr missense
mutation (Daehmlow et al. 2002).
In addition the MYBPC3 Arg502Trp mutation with a
frequency of about 2.4% is the most common HCM-
causing mutation among individuals of European descent
in the USA (Saltzman et al. 2010). However other muta-
tions may be prevalent in different European populations,
such as in the Netherlands, where three different founder
mutations are present: (i) the c.2373_2374insG MYBPC3
which is present in the great majority of HCM patients (up
to 25%) and where (ii) the c.2864_2865delCT and (iii) the
c.2827C[T mutations occur in about 5% of HCM
patients each (Alders et al. 2003; Christiaans et al. 2010).
Beside the important mutations in MYBPC3, MYBPC1
mutationsareacauseofdistalarthrogryposistype1(DA1),a
disease characterized by congenital contractures of the
hands and feet (Gurnett et al. 2010).
Although by now MYBPC3 mutations are well known
causes of HCM and DCM including associated heart fail-
ure, the underlying molecular mechanisms are not well
deﬁned, some of which will be discussed in the next
chapters.
Animal models
To gain more insight into the underlying molecular
mechanisms, Mybpc3 has been deleted in genetically
altered mouse models by two independent groups. Loss of
this protein is not associated with any embryonic lethality
and MYBPC3 also is not essential for sarcomere formation
but its absence results in profound eccentric hypertrophy in
the homozygous animals (Carrier et al. 2004; Harris et al.
2002). Hemodynamic analysis in the mice generated by the
Carrier group, where exons 1 and 2 have been deleted,
revealed the presence of normal contractility but severe
diastolic defects. In addition heterozyogous animals
develop septal hypertrophy, a hallmark of HCM (Carrier
et al. 2004). However these animals were engineered so
that they harbour a complete ablation of the gene and
therefore are useful to identify basic mechanisms, but the
overwhelming majority of human mutation carriers express
mutant mRNAs and probably proteins, which makes it
difﬁcult to relate these data directly to the situation in
patients.
Therefore, in addition to the pure knockout models,
wildtype Mybpc3 and different Mybpc3 mutants have been
overexpressed in various models such as an amino-terminal
truncated MYBPC3, which mimics a certain type of human
mutations which lead to the loss of the carboxyterminal
domains including the titin and myosin binding sites.
Overexpression of the mutant, but not the wildtype protein,
caused major features of HCM including hypertrophy and
an increase in calcium sensitivity (Yang et al. 1998).
Whereas above mentioned transgenes were well
expressed at the mRNA and protein levels, overexpression
of a Mybpc3 mutant lacking only the myosin binding
domain resulted in the expression of only very modest
levels of mutant protein (i.e. about 5%) which led to a mild
hypertrophy and heart failure phenotype (Yang et al. 1999).
Two additional knock in mouse models have been
engineered to carry mutations found in patients and which
affect titin and myosin binding. Interestingly animals
homozygous for these mutations develop a DCM like
phenotype with depressed contractility and hypertrophy
(McConnell et al. 1999). Another knock in mouse model
was generated such that the mutant protein did not contain
the aminoterminal myosin binding domain. The mutant
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erozygous and homozygous animals, was PKA phospho-
rylatable and major structural defects could not be
detected. However this mutation was associated with a
signiﬁcant increase in calcium sensitivity (Witt et al. 2001).
An additional mouse knock in model, based on a G[A
transition located on the last nucleotide of exon 6 and
which was found in a patient with HCM, has been gener-
ated by Lucie Carrier’s group. Interestingly this mutation
gives rise to three different mRNAs: (i) missense mutation
(ii) nonsense due to exon skipping, frameshift and pre-
mature stop codon and (iii) deletion/insertion as nonsense
but with additional partial retention of a downstream intron
which restores the reading frame and which leads to an
almost full length protein. Homozygous animals develop
hypertrophy, interstitial ﬁbrosis and decreased myocardial
function whereas heterozygous animals do not have any
obvious phenotype (Vignier et al. 2009).
Additional genetically altered mouse models have been
generated to study MYBPC3 phosphorylation, which will
be discussed in the next chapter.
Phosphorylation
Human MYBPC3 contains at least four phosphorylation
sites which are localized inside the myosin binding motif
(serines 275, 284, 304, with an additional phosphorylation
site not unequivocally identiﬁed) (Copeland et al. 2010)),
the mouse myosin binding motif contains three to four sites
(serines 273, 282, 302, (305)) and ﬁve sites have been
identiﬁed in the canine genome as well as three sites in the
rat genome (Jia et al. 2010; Yuan et al. 2006, 2008). These
phosphorylation sites are targets of protein kinase A (PKA;
serines 273, 282, 302) (Gautel et al. 1995), protein kinase C
(PKC; serines 273, 302) (Mohamed et al. 1998), calmod-
ulin dependent kinase II (CamKII; serine 302) (Gautel
et al. 1995), protein kinase D (PKD; serine 302) (Bardswell
et al. 2010) and ribosomal S6 kinase (RSK; serine 282)
(Cuello et al. 2011).
MYBPC3 phosphorylation also has been studied in
various transgenic mouse models, for example lines have
been established where the phosphorylation sites (Ser273,
Ser282, and Ser302), along with two adjacent sites that
could be potentially phosphorylated (Thr272, Thr281),
were converted to alanines. While overexpression of
wildtype MYBPC3 was able to rescue the MYBPC3 null
phenotype, the non-phosphorylatable MYBPC3 was not
(Sadayappan et al. 2005). Also a similar approach has been
used to analyze MYBPC3 phosphorylation by generating
animals whereby only the three known phosphorylation
sites were converted into alanines (t3SA). Again these
animals showed, when crossed into the Mybpc3 null
background, in addition to hypertrophy systolic and dia-
stolic defects, further supporting the notion that PKA
phosphorylation of MYBPC3 is important for myocardial
function (Tong et al. 2008). Another type of transgenic
animals, where the phosphorylation motif ‘‘LAG-
AGRRTS’’ was completely deleted, where also generated.
These animals showed an increase in contractility and
relaxation of about 22 and 25%, respectively. An increase
in the phosphorylation of the remaining MYBPC3 and
other proteins such as troponin I and phospholamban was
also observed (Yang et al. 2001).
The reverse experiment, i.e. overexpression of a
phosphomimetic MYBPC3 in a Mybpc3 null background,
has also been performed, which resulted in subtle changes
in sarcomeric ultrastructure characterized by increased
distances between the thick ﬁlaments which may indicate
that phosphomimetic MYBPC3 affects thick–thin ﬁlament
relationship. The phosphomimetic MYBPC3 also pre-
vented interaction with myosin heavy chain in vitro as
analyzed by yeast two hybrid and pull down assays.
Moreover these transgenic animals were also resistant to
ischemia reperfusion injury. This effect is difﬁcult to
explain, but it may well be that phosphomimetic MYBPC3
prevents an increase of thick ﬁlament packing density
which is associated with reduced calcium activated force
generation. An alternative explanation could be that
phosphorylated MYBPC3 is protected from calpain (see
also later) mediated proteolysis (Sadayappan et al. 2006,
2009). In this context it is probably important to mention,
that loss of MYBPC3 phosphorylation also has been
observed in failing human hearts and strategies to increase
its phosphorylation may have cardio-protective effects
(Copeland et al. 2010; Sadayappan et al. 2006).
Above mentioned studies have been intensiﬁed by
generating mouse models overexpressing various single or
double phosphomimetic or non phosphorylatable serines in
the Mybpc3 knockout background (i.e. the cMyBP-C
SAS(t/t),
cMyBP-C
ADA(t/t), cMyBP-C
DAD(t/t); on position S-273,
S-282 and S-302, respectively). One major conclusion of
these studies is that S-282 has a unique regulatory role in
that its phosphorylation is critical for the subsequent
phosphorylation of S-302, but that all residues play a role
in regulating the contractile response to b-agonist stimu-
lation (Sadayappan et al. 2011).
Although there is now compelling evidence supporting
the notion that MYBPC3 phosphorylation modulates con-
tractility by controlling the proximity of the myosin heads
to actin, however the precise molecular mechanism
remains unclear (reviewed in (Bareﬁeld and Sadayappan
2010; Schlossarek et al. 2011)). In particular when using in
vitro systems it was shown that MYBPC3 phosphorylation
can abolish the ability of MYBPC3 to interact with the
S2 region of the myosin heavy chain but may enhance
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dephosphorylation results in strong binding of MYBPC3 to
the myosin head, probably preventing its force generating
strong interaction with actin (Kulikovskaya et al. 2003a;
Sadayappan et al. 2006). However recent data also indicate
that MYBPC3 may act synergistically with the myosin
RLC to enhance cross-bridge formation by altering the
interaction of the myosin head with actin. It may well be
that this interaction depends on phosphorylation of either
MYBPC3 or RLC and may well be able to provide another
mechanism how phosphorylation of sarcomeric proteins
may affect protein/protein interactions and kinetics of force
development (Colson et al. 2010). Although it is well
known that the distance between thick and thin ﬁlaments is
a major determinant of calcium sensitivity and that loss of
MYBPC3 is associated with increased calcium sensitivity,
the precise molecular mechanism of how MYBPC3 phos-
phorylation affects this system is unknown. Part of this
problem is that PKA phosphorylation decreases calcium
sensitivity via troponin I phosphorylation which leads to a
decrease in tropinin C calcium sensitivity. However
MYBPC3 phosphorylation, which decreases calcium sen-
sitivity, has no effect on interﬁlament spacing (Colson et al.
2010) (for more details on calcium sensitivity see also next
chapter). Future studies, based on various transgenic ani-
mals, will certainly help to answer this question.
MYBPC3 mutations and molecular mechanisms leading
to myocardial dysfunction
In general two different molecular mechanisms may
account for the observed pathologic effects of any muta-
tion: (i) poison peptide (functional integration of a mutant
protein) (ii) haploinsufﬁciency (loss of one allele).
However, any mutation may also cause disturbances in
the degradation of such a product, including its mRNA. For
example, the mRNA might be degraded via nonsense
mediated mRNA decay or the protein may be degraded via
the ubiquitin proteasome system (UPS) with implications
for protein degradation in general, including autophagy.
Most of the more than 600 known HCM causing
mutations located in other sarcomeric protein genes are
point mutations or single amino acid deletions (Van Driest
et al. 2004), hence the poison peptide mechanism seems to
be the likely mechanism for these mutations. In contrast,
the most frequent type of MYBPC3 mutation affects splice
acceptor and donor sites or are deletions or insertions
predicted to result in truncated MYBPC3 proteins (Van
Driest et al. 2004).
However, multiple studies were unable to detect or
document the presence of the predicted truncated MY-
BPC3 molecules. For example van Dijk and colleagues
analyzed the c.2373dupG and the c.2864_2865delCT
mutations and found a signiﬁcant decrease in mutant MY-
BPC3 mRNA. Also they detected a signiﬁcant loss of
MYBPC3 protein but were unable to detect the truncated
proteins (van Dijk et al. 2009). Marston and colleagues
studied MYBPC3 protein expression in two patients car-
rying the Glu258Lys and the Arg502Trp missense muta-
tions in addition to seven other mutations which are
predicted to lead to premature terminations and truncated
proteins. However no truncated protein was detectable and
in all samples studied signiﬁcant lower amounts of MY-
BPC3 protein was detected (Marston et al. 2009). Another
complex mutation where a T to A transition occurred on
position 2604 together with a deletion of C at 2605 was
predicted to lead to a truncated protein (1-868 ? 13 non-
sense amino acids with a premature stop codon in C7) was
also studied in great detail, but no truncated MYBPC3
protein could be detected (Jacques et al. 2008). In sum-
mary, several different studies failed to detect truncated
MYBPC3 proteins in MYBPC3 mutation carriers, which
makes the poison peptide mechanism unlikely to occur in
the studied mutations/individuals. Also these studies
documented loss of MYBPC3 protein in mutations carri-
ers, with only 67–75% of the normal protein present,
which indicates haploinsufﬁciency may contribute to the
phenotype.
MYBPC3 plays a modulatory role in the regulation of
actin–myosin interaction and by binding to both proteins it
may directly affect calcium sensitivity. By employing
skinned myocytes from patients with HCM mutations, a
variety of studies showed that MYBPC3 mutations are
associated with higher calcium sensitivity. However, these
data may also result from low levels of troponin I (TnI)
phosphorylation present in the myectomy tissue rather than
the mutation itself (Hoskins et al. 2010; Jacques et al. 2008;
van Dijk et al. 2009). Nevertheless an increase in calcium
sensitivity in myocardial samples obtained from patients
affected by MYBPC3 mutations is likelybecause removal of
MYBPC3 from myocardial samples under experimental
conditions is associated with an increase in calcium sensi-
tivity (Hofmann et al. 1991a, b; Kulikovskaya et al. 2003b)
and an increase in calcium sensitivity has also been shown
in Mybpc3 deﬁcient myocardium (Rybakova et al. 2011).
Calcium sensitivity depends on the rate of calcium binding
to or calcium release from troponin C and kinetic studies
suggest that for HCM causing mutations the rate of calcium
binding to TnC is increased, but it remains to be elucidated
whether this is a general phenomenon or whether other
determinants of calcium sensitivity such as the TnC–
calcium dissociation rate may also be affected and whether
this holds true for MYBPC3 mutations (Dong et al. 2008).
Therefore, MYBPC3 mutations may primarily increase
calcium sensitivity (gain of function) which may cause
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may also cause incomplete relaxation, a cause of diastolic
dysfunction frequently observed in HCM. This concept
also is supported by hemodynamic data obtained from
Mybpc3 deﬁcient animals, where no systolic but severe
diastolic dysfunction has been observed (Carrier et al.
2004).
It might well be that MYBPC3 mutations are primarily
linked to an increase in calcium sensitivity, but it is difﬁ-
cult to link this event directly to the secondary effects such
as myocardial hypertrophy including myoﬁbrillar disarray,
fatal arrhythmias and sudden cardiac death (Fig. 4). One
hypothesis proposes energy deﬁciency due to reduced
thermal efﬁciency in HCM or another hypothesis states that
troponin C functions as an intracellular calcium buffer or
calcium store (Bers 2008). An increase in calcium sensi-
tivity could affect calcium transients, which indeed have
been found to be increased in Myh6 Arg403Gln knock in
animals (Gao et al. 1999). An increase in calcium transients
may also have effects on calcium dependent enzymes such
as calcineurin, calmodulin dependent kinase, and protein
kinase C all of which have been shown to be important for
the initiation of myocardial hypertrophy (Kubis et al.
2003).
The hypothesis that sarcomeric HCM mutations lead to
inefﬁcient ATP utilization was proposed by the Watkins
group and is an attractive model, because it is able to
explain many different features found in HCM (Ashraﬁan
et al. 2003). According to this theory a lower ATP/
ADP ? P ratio may contribute to energy depletion in
critical compartments, which may affect calcium re-uptake
and lead to an increase in calcium concentrations and thus
activation of calcium dependent enzymes such as calci-
neurin. Another consequence is the activation of adenosine
monophosphate kinase (AMPK), which is also able to
induce hypertrophy and yet another consequence is the
increase in mitochondrial demands which may lead to an
increase in reactive oxygen species, mitochondrial abnor-
malities and apoptosis—all of which have been observed in
various patients affected by HCM (Ishikawa et al. 2005;
Kavantzas et al. 2000; Unno et al. 2009).
As pointed out above most MYBPC3 mutations lead to
haploinsufﬁciency but some missense mutations might
escape targeted removal and might well be expressed in the
myocardium. This might particularly be true for the
reported aminoterminal mutations G5R, R35W and T59A
in the human genome (Sarcomere Protein Gene Mutation
Data Base) as well as for the A31P mutation observed in
Maine Coon cats (Meurs et al. 2005), all of which are
linked to HCM. Ratti and co-workers (Ratti et al. 2011)
studied above mentioned missense mutations. While G5R
had only mild effects, A31P could not be expressed as a
soluble protein and T59A was not chosen as in many other
species a threonine residue is substituted by an alanine and
no extreme effects were expected, the R35W seemed to be
important for binding to RLC.
MYBPC3 mutations by modulating calcium sensitivity
may also have effects, either directly or indirectly, on me-
chanosensation and mechanotransduction. For example,
changesincalciumtransientscausedeitherviaanincreasein
calcium sensitivity or via inefﬁcient ATP usage, may have
effects on calcium dependent enzymes which may in turn
affect mechanosensory effects. For example, calcineurin
mediated NFAT and GATA4 activation, protein kinase C
mediated effects on MYBPC3 itself or calmodulin kinase II
effects on phospholamban and or ryanodine receptor phos-
phorylation may contribute to changes in gene expression
and myocardial remodelling. Myocardial hypertrophy and
remodelling itself may lead to changes in bio-mechanical
properties of the heart, which feeds back to changes in
intracellular signalling (Kno ¨ll et al. 2002, 2010). The sar-
comeric Z-disc is a central nodal point for signalling (Kno ¨ll
et al. 2011a) and changes in Z-disc structure or composition
may well affect its function. In this context, the E3 ubiquitin
ligase atrogin 1 has been found to colocalize at the
Fig. 4 Summary of possible pathologic events caused by a primary
increase in calcium sensitivity, which has been shown to be present in
various Mybpc3 transgenic animal models as well as in patients
affected by mutations in the MYBPC3 gene. CamKII calmodulin
dependent kinase II, PKC protein kinase C
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have consequences for Z-disc mediated signalling (Mearini
et al. 2010) (see also later). However it remains unclear
whetherabovementionedchangesinintracellularsignalling,
if not alone able to cause effects, will sensitize the myocar-
dium at predisposed locations to maladaptation. This may
include the possibility of increased shear stress causing
septalhypertrophy.ItalsoremainstobeseenwhetherZ-disc
mediated apoptotic events play a role in MYBPC3 related
HCM (Kno ¨ll et al. 2011c).
It remains also unclear, how MYBPC3 mutations are
linked to ﬁbrosis as well to intracellular and cellular myo-
ﬁbrillar disarray. It might well be that ﬁbrosis, which is
probablyanearlyeventinHCM,causesmyoﬁbrillardisarray
by displacing existing cardiac myocytes, but it remains
unclear how intracellular disarray develops. In this context,
myoﬁbrillar disarray contributes certainly to inefﬁcient
energy use (i.e. cardiac myocytes are not aligned properly).
ArecentstudyonHCMmyocardialbiopsies,includingthose
from patients affected by MYBPC3 mutations, supports the
view that ﬁbrosis is anearly event and ispresent even before
the onset of hypertrophy (Ho et al. 2010). Inhibition of
ﬁbrosis,eitherviaantiTGFbantibodiesortheangiotensinII
type 1 receptor antagonist losartan prevented onset of
hypertrophy, non myocyte proliferation and ﬁbrosis in
genotype positive but hypertrophy negative (pre-hypertro-
phic) animals (Teekakirikul et al. 2010). These data point as
well to the importance of other cell types than cardiac
myocytes which are inherent in the myocardium and which
contributesigniﬁcantlytothephenotype(Kno ¨lletal.2011b).
A novel link between an increase in myoﬁbrillar calcium
sensitivity and arrhythmias has been uncovered recently.
An increase in calcium sensitivity led to a change in the
shape of the ventricular action potentials in mice which
results in shorter effective refractory periods, greater beat
to beat variability of action potential durations and
increased dispersion of ventricular conduction velocities at
higher heart rates—all of which may predispose to the
occurrance of arrhythmias. These effects were greatest in
HCM causing troponin T mutant animals and most
importantly, these effects were reproduced when the cal-
cium sensitizer EMD57033 was used and they were
reversible when blebbistatin, a calcium de-sensitizer, was
employed. Another important ﬁnding of this study is that
the degree of myocardial hypertrophy does not correlate
with the arrhythmia risk (Baudenbacher et al. 2008). Other
mechanisms may involve above mentioned energy deple-
tion with consecutive effects on energy dependent ion
exchanges (Ashraﬁan et al. 2003), loss of cardiac myocytes
via apoptosis, necrosis or autophagy which may lead to
electric isolation of single cardiac myocytes and ﬁbrosis
(Teekakirikul et al. 2010), all of which have been shown to
contribute to arrhythmogenic events.
Another important approach has been used by Lucie
Carrier’s group, when they analyzed the degradation pro-
cess of MYBPC3. This group found that the E3 ubiquitin
ligase atrogin 1 interacts with both, mutant (a 32 kDa
MYBPC3 truncated protein, based on a human mutation
and which comprises only of domains C0 and parts of C1
termed M7t-cMyBP-C) and wildtype MYBPC3, but only
the mutant MYBPC3 was targeted for degradation. This
makes atrogin 1 also a novel MYBPC3 interacting protein,
but whether the interaction of atrogin 1 and full length
wildtype MYBPC3 is physiologically relevant remains to
be seen. Interestingly atrogin 1 and M7t-cMyBP-C co-
localize at the sarcomeric Z-disc, which points to the
importance of this structure in protein degradation pro-
cesses (Mearini et al. 2010) (reviewed in: (Kno ¨ll et al.
2011a)). Their data also indicated that muscle ring ﬁnger
protein 1 (MuRF1) regulates MYBPC3 mRNA and protein
via a posttranscriptional mechanism (Mearini et al. 2010).
Also, calpain 1, a ubiquitously expressed calcium depen-
dent protease and which localizes to the sarcomeric Z-disc
and I-band via interactions with titin, interacts with
MYBPC3 as well and might contribute to MYBPC3 turn-
over (Jiang et al. 2002; Kontrogianni-Konstantopoulos
et al. 2009). In addition, the lysosomal inhibitor baﬁlo-
mycin A1 caused an increase in truncated MYBPC3 pro-
teins, which points to the possible involvement of
autophagy in MYBPC3 related degradation processes.
As brieﬂy mentioned above, domains C5–C8 have been
hypothesized to interact with one another, forming a ‘‘tri-
meric collar’’ that constrains the thick ﬁlament. Interest-
ingly, mutations R654H and N755K, both are HCM
causing and located in C5, decreased the afﬁnity to C8
about 2-fold and by at least 10-fold, respectively (Mool-
man-Smook et al. 2002). Disturbances of intra- MYBPC3
interactions by mutations are a completely novel approach
to explain the complex phenotype observed in genetically
altered animal models as well as in human patients.
Implications for therapy
MYBPC3 mutations like the majority of all other cardio-
myopathy causing mutations are associated with incom-
plete, age and gender dependent penetrance. Powerful
epigenetic and environmental factors are thought to have a
major impact on the phenotype, which also implies the
possibility of effective therapeutical interventions.
Ifincreasedcalciumsensitivityistheprimaryeventwhich
leads to HCM in MYBPC3 mutation carriers then calcium
desensitizers might be able to inﬂuence positively disease
progression, which has been shown in animal models
(Baudenbacheret al. 2008) (see also above). However DCM
is associated with decreased calcium sensitivity and precise
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123calibration of calcium sensitivity is certainly important and
needs to be monitored properly, if applied in therapy.
Another although still very experimental approach is to use
short oligonucleotides to intervene in mRNA processing
suchthat‘‘exonskipping’’eventscanbeusedtherapeutically
to prevent the synthesis of pathologic mRNAs or to use
siRNAs/miRNAs to suppress pathologic mRNAs—an
approach potentially important for MYBPC3 mutations.
Calcium antagonists such as diltiazem have been success-
fully used to suppress HCM in the R403Q alpha MHC
transgenic mouse (Semsarian et al. 2002) as well as in a
mouse model carrying the TnT-I79 N mutation (Wester-
mann et al. 2006), which led to an ongoing human trial
(NCT00319982). However it will be important to ﬁnd out,
whether MYBPC3 mutation positive patients will respond
appropriately to this type of treatment.
Also overexpression of SERCA2a in a Glu180Gly
tropomyosin (Pena et al. 2010) as well as parvalbumin
overexpression in a Glu180Gln tropomyosin animal model
rescued the phenotype in both of these lines, which points
to the possibility of manipulating the calcium metabolism
in order to treat the disease (Coutu et al. 2004). However
while phospholamban ablation in muscle LIM protein
deﬁcient (Minamisawa et al. 1999) and in Glu180Gly
tropomysin transgenic animals (Alves et al. 2010; Gafﬁn
et al. 2011) is favourable, ablation of the very same gene in
Mybpc3 transgenic animals is not (Song et al. 2003). It
remains to be determined whether these differences are due
to the well known differences between human and mouse
physiology or whether these differences reﬂect differences
in the underlying molecular mechanisms.
Another possibility might be to intervene at the level of
energy metabolism via perhexiline which shifts substrate
utilization away from free fatty acids to carbohydrates by
inhibiting the enzyme carnitine palmitoyl transferase.
Perhexiline improved cardiac energetics, normalized
exercise diastolic dysfunction and increased exercise
capacity in patients (Abozguia et al. 2010; Lele et al.
1995).
It remains also to be seen whether moderate physical
activity in MYBPC3 mutation carriers is favourable, as
suggested by animal experimentation (Konhilas et al.
2006), and anti-apoptotic strategies may prove helpful as
well. Indeed anti-apoptotic gene expression has been
observed when animals were subjected to limited physical
exercise (Konhilas et al. 2006). Also calcineurin inhibition
may have favourable effects as suggested by animal
experimentation (Sussman et al. 1998), but application of
available calcineurin inhibitors such as cyclosporine A and
tacrolimus, at doses needed to affect calcineurin activity in
the heart, is associated with signiﬁcant side effects such as
hypertension, nephro-toxicity and diabetes, which pre-
cludes their application in human individuals.
Another way to inhibit hypertrophy is to use statins (3-
hydroxy-3-methyglutarylcoenzyme A reductase inhibitors),
which act via reducing membrane bound Ras and thus
reducing pERK44/42 and ERK1/2 activation which
reduced HCM related symptoms in a R403Q beta MHC
transgenic rabbit model (Patel et al. 2001; Senthil et al.
2005). However human pilot studies based on these animal
experiments remained disappointing (Bauersachs et al.
2007; Nagueh et al. 2010). Therefore it remains to be
determined whether this approach is not applicable in
general or whether a genotype–phenotype speciﬁc analysis
will identify patient subgroups more susceptible to this
type of treatment.
Summary
Although MYBPC3 has been the subject of intense
research for almost over four decades, our understanding of
its function in physiology and patho-physiology is still
limited. However, MYBPC3 mutations are a major cause of
human cardiomyopathy and associated heart failure, with
some disease causing mutations having frequencies of up
to 4% in various populations. Most MYBPC3 mutations
lead to haploinsufﬁciency and to a primary increase in
calcium sensitivity. This may explain major features
observed in patients such as the hypercontractile pheno-
type, changes in calcium transients, myocardial hypertro-
phy, the defect in relaxation and effects on remodelling
including the development of myoﬁbrillar disarray as well
as the link to live threatening arrhythmias (Fig. 4).
Future research will focus on the identiﬁcation of
pathways leading from a single MYBPC3 mutation to the
complex disease phenotype in patients. These pathways
should be deﬁned for every single ‘‘private’’ mutation.
Although challenging and certainly difﬁcult to achieve, this
approach will undoubtedly result in the development and
design of patient speciﬁc, novel therapies. Inducible plu-
ripotent stem cells (iPS), gene therapy approaches, whole
genome sequencing and determination of the explicit
genotypes, as well as medicinal chemistry will have to be
combined to increase our knowledge in this ﬁeld.
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